10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2020 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2020 10-K (Filed: Feb 8, 2021) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2020 | Dec 31, 2019 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 2,193,700 | 1,617,800 |
| Marketable securities | 1,393,300 | 1,596,500 |
| Accounts receivable - trade, net | 3,111,500 | 2,100,000 |
| Inventories | 1,916,600 | 1,415,500 |
| Prepaid expenses and other current assets | 160,800 | 273,700 |
| Total current assets | 9,779,100 | 7,689,100 |
| Marketable securities | 3,135,600 | 3,256,800 |
| Property, plant, and equipment, net | 3,221,600 | 2,890,400 |
| Deferred tax assets | 858,900 | 824,200 |
| Other noncurrent assets | 168,100 | 144,700 |
| Total assets | 17,163,300 | 14,805,200 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 475,500 | 418,100 |
| Accrued expenses and other current liabilities | 1,521,800 | 1,211,400 |
| Other liabilities - Sanofi | 122,400 | 85,000 |
| Total current liabilities | 2,697,400 | 2,096,600 |
| Long-term debt | 1,978,500 | 0 |
| Finance lease liabilities | 717,200 | 713,900 |
| Total liabilities | 6,138,000 | 3,715,500 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none | 0 | 0 |
| Additional paid-in capital | 6,716,200 | 4,428,600 |
| Retained earnings | 10,893,000 | 7,379,800 |
| Accumulated other comprehensive income | 29,300 | 21,100 |
| Treasury Stock, at cost; 16,431,520 shares in 2020 and 4,860,123 shares in 2019 | (6,613,300) | (739,900) |
| Total stockholders' equity | 11,025,300 | 11,089,700 |
| Total liabilities and stockholders' equity | 17,163,300 | 14,805,200 |
| Project | ||
| Sanofi | ||
| Accounts receivable | 404,700 | 260,600 |
| Deferred revenue, current | 341,700 | 310,500 |
| Deferred revenue, noncurrent | 16,700 | 27,700 |
| Other noncurrent liabilities | 189,300 | 482,000 |
| Other | ||
| Accounts receivable | 598,500 | 425,000 |
| Deferred revenue, current | 236,000 | 71,600 |
| Deferred revenue, noncurrent | 41,100 | 77,600 |
| Other noncurrent liabilities | 497,800 | 317,700 |
| Class of Stock | ||
| Class A Stock | ||
| Common stock | 0 | 0 |
| Common Stock | ||
| Common stock | 100 | 100 |
| Total stockholders' equity | 100 | 100 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |